| Patient | Gilda Radner |
|---|---|
| Date of birth | 1946-06-28 |
| Identifiers | MRN HR-ML026-SYN-TD; SSN (made up) 000-26-8821 |
| Document date | 2026-11-01 |
| Author | Delia Marchand, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four weeks of bloating, early fullness and pelvic pain in a woman of 39: symptom index, pelvic examination, CA-125, and same-week imaging. Concerns: Four weeks of bloating that makes her clothes tight, feeling full after a few bites, a dull ache low in the abdomen and pelvis, and passing urine more often, on most days; she has been more tired than usual for longer than that; Afraid this is cancer: her father died of a brain tumor and ovarian cancer runs in her family; she wants to be taken seriously and told plainly. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Enoxaparin 40 mg/0.4 mL prefilled syringe, 40 mg under the skin once daily for 28 days after surgery | 40 mg under the skin once daily for 28 days | Subcutaneous route | 1986-04-21 to 1986-05-18 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a day | Two tablets every 6 hours as needed | Oral route | 1986-04-21 to 1986-05-05 | completed | S |
| Carboplatin 10 mg/mL injection, 610 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cycles | Day 1 every 21 days for six cycles | Intravenous route | 1986-05-12 to 1986-08-25 | completed | S |
| Paclitaxel 6 mg/mL injection, 275 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidine | Day 1 every 21 days for six cycles | Intravenous route | 1986-05-12 to 1986-08-25 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea | One tablet every 8 hours as needed for nausea | Oral route | 1986-05-12 | active | S |
| Olaparib 150 mg oral tablet, two tablets (300 mg) by mouth twice daily with food, as maintenance for up to two years | Two tablets twice daily with food | Oral route | 1986-09-15 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Transvaginal ultrasound of the pelvis: a 9.2 cm solid and cystic right adnexal mass and a 5.1 cm solid left adnexal mass, both with irregular solid parts and strong internal blood flow; moderate ascites; uterus normal (O-RADS 5) | 1986-04-07 to 1986-04-07 | completed | S |
| CT of the chest, abdomen and pelvis with contrast: bilateral adnexal masses, moderate ascites, omental caking up to 4 cm, a 1.2 cm nodule on the right hemidiaphragm, and small pelvic peritoneal nodules; no enlarged lymph nodes, no liver or lung lesion, and no pleural effusion | 1986-04-08 to 1986-04-08 | completed | S |
| Ultrasound-guided core needle biopsy of the omentum: high-grade serous carcinoma, PAX8 and WT1 positive, p53 aberrant (Mullerian origin); CK7 positive, CK20 negative | 1986-04-10 to 1986-04-10 | completed | S |
| Primary cytoreductive surgery by gynecologic oncology: laparotomy, total abdominal hysterectomy with bilateral salpingo-oophorectomy, total omentectomy, stripping of the right hemidiaphragm peritoneum, and excision of pelvic peritoneal nodules, with no visible residual disease (complete gross resection); lymph nodes not removed because none were enlarged. Pathology: high-grade serous carcinoma of both ovaries with serous tubal intraepithelial carcinoma in the right fallopian tube; omental deposit 4.5 cm, diaphragm 1.3 cm; ascitic fluid positive; pT3c, FIGO stage IIIC | 1986-04-21 to 1986-04-21 | completed | S |
| Genetic counseling before germline testing: three-generation pedigree, Ashkenazi Jewish ancestry, the meaning of positive, negative and uncertain results for her and for her blood relatives, and consent for a multigene panel | 1986-04-14 to 1986-04-14 | completed | S |
| Advance care planning conversation, about 20 minutes | 1986-10-13 to 1986-10-13 | completed | S |
| CT of the chest, abdomen and pelvis with contrast at the end of chemotherapy: no ascites, no peritoneal or omental nodule, no enlarged lymph node, and no liver or lung lesion; expected postoperative changes (no evidence of disease) | 1986-09-08 to 1986-09-08 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1981-09-20 | Tdap vaccine | completed | S |
| 1986-10-13 | Influenza vaccine, this season (inactivated) | completed | S |
| 1986-10-13 | COVID-19 mRNA vaccine, this season's formula | completed | S |
| 1986-10-13 | Pneumococcal conjugate vaccine (PCV20) | completed | S |
| 1986-10-13 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1975 to 1980 | Bulimia during her television career in the late 1970s, which she later wrote about; no treatment recorded in the cited source | D (CLM-0008) |
| About 1985 | Two miscarriages and an unsuccessful round of in vitro fertilization in her late thirties | D (CLM-0007) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| father | Brain cancer; died when she was fourteen | D (CLM-0003) | |
| grandmother | Ovarian cancer; side of the family not recorded in the cited source | D (CLM-0003) | |
| aunt | Ovarian cancer; side of the family not recorded in the cited source | D (CLM-0003) | |
| cousin | Ovarian cancer; side of the family not recorded in the cited source | D (CLM-0003) |
| Concern | Status | Evidence |
|---|---|---|
| Four weeks of bloating that makes her clothes tight, feeling full after a few bites, a dull ache low in the abdomen and pelvis, and passing urine more often, on most days; she has been more tired than usual for longer than that | active | S |
| Afraid this is cancer: her father died of a brain tumor and ovarian cancer runs in her family; she wants to be taken seriously and told plainly | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 10.6 on 1986-10-13; Leukocytes [#/volume] in Blood by Automated count 4.2 on 1986-10-13; Platelets [#/volume] in Blood by Automated count 182 on 1986-10-13; Sodium [Moles/volume] in Serum or Plasma 136 on 1986-04-06; Potassium [Moles/volume] in Serum or Plasma 4.2 on 1986-04-06; Creatinine [Mass/volume] in Serum or Plasma 0.69 on 1986-09-15; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1981)/1.73 sq M 113 on 1986-09-15; Glucose [Mass/volume] in Serum or Plasma 88 on 1986-04-06; Calcium [Mass/volume] in Serum or Plasma 9.4 on 1986-04-06; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 19 on 1986-09-15; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 20 on 1986-05-12; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 84 on 1986-04-06; Bilirubin.total [Mass/volume] in Serum or Plasma 0.4 on 1986-09-15; Albumin [Mass/volume] in Serum or Plasma 3.7 on 1986-05-12; Cancer Ag 125 [Units/volume] in Serum or Plasma 9 on 1986-09-15; Carcinoembryonic Ag [Mass/volume] in Serum or Plasma 1.6 on 1986-04-06; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 1986-04-06; Pain severity - 0-10 verbal numeric rating [Score] - Reported 2 on 1986-05-12; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 2 on 1986-10-13; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 8 on 1986-04-14; Neutrophils [#/volume] in Blood by Automated count 2.4 on 1986-10-13; Magnesium [Mass/volume] in Serum or Plasma 1.7 on 1986-07-14; Cholesterol [Mass/volume] in Serum or Plasma 186 on 1986-10-13; Cholesterol in HDL [Mass/volume] in Serum or Plasma 58 on 1986-10-13; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 108 on 1986-10-13; Triglyceride [Mass/volume] in Serum or Plasma 98 on 1986-10-13; Total score [AUDIT-C] 1 on 1986-10-13 [S]
Strengths and supports: Supports: her spouse and close friends from work; humor is how she copes. She decides who is told about her health [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Persistent bloating with tightness of her clothes, feeling full after a few bites, a dull lower abdominal and pelvic ache, and passing urine more often, on most days for about four weeks, in a woman of 39: the ovarian cancer symptom index is positive. Examination: a distended abdomen with shifting dullness and a firm, fixed, irregular mass in the right adnexa. Suspected ovarian cancer; transvaginal ultrasound, CT, CA-125 and gynecologic oncology review booked within the week | resolved | confirmed | R19.00 | S — Synthetic presenting problem linked to her documented abdominal symptoms; superseded by the diagnosis at the gynecologic oncology consultation. |
| High-grade serous carcinoma of both ovaries (Mullerian origin), diagnosed by image-guided omental core biopsy (PAX8 and WT1 positive, p53 aberrant), with bilateral adnexal masses, ascites, omental and diaphragmatic disease on CT: clinical FIGO stage IIIC; synthetic modern detail linked to her documented ovarian cancer | active | confirmed | C56.3 | S — Synthetic histology and stage; the documented diagnosis was stage IV ovarian cancer (D). |
| Peritoneal and omental metastases of the ovarian cancer, with ascites | active | confirmed | C78.6 | S — Synthetic extent of disease on CT and biopsy. |
| Family history of ovarian cancer in three relatives (her grandmother, an aunt, and a cousin) in a woman of Ashkenazi Jewish ancestry; no genetic testing in the family is known | active | confirmed | Z80.41 | S — Synthetic coding of her documented family history; the basis for genetic counseling. |
| Acute viral upper respiratory infection on day 8 of the second chemotherapy cycle: two days of sore throat, runny nose and a dry cough, without fever; rapid influenza and COVID-19 tests negative; resolved | resolved | confirmed | J06.9 | S — Synthetic acute infection; not a historical claim. |
| Symptomatic surgical menopause after bilateral salpingo-oophorectomy at 39: hot flashes and night sweats | active | confirmed | E89.41 | S — Synthetic consequence of the synthetic operation. |
| Chemotherapy-induced peripheral neuropathy from paclitaxel: tingling in the toes and fingertips, grade 1 (sensory only, no effect on daily activities) | active | confirmed | G62.0 | S — Synthetic common effect of paclitaxel. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1986-04-06 | Hemoglobin [Mass/volume] in Blood | 12.4 | g/dL | 11.6-15 g/dL | Normal | S |
| 1986-04-06 | Leukocytes [#/volume] in Blood by Automated count | 7.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1986-04-06 | Platelets [#/volume] in Blood by Automated count | 412 | 10*3/uL | 150-400 10*3/uL | High | S |
| 1986-04-06 | Sodium [Moles/volume] in Serum or Plasma | 136 | mmol/L | 135-145 mmol/L | Normal | S |
| 1986-04-06 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1986-04-06 | Creatinine [Mass/volume] in Serum or Plasma | 0.72 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1986-04-06 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1981)/1.73 sq M | 109 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1986-04-06 | Glucose [Mass/volume] in Serum or Plasma | 88 | mg/dL | 70-99 mg/dL | Normal | S |
| 1986-04-06 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1986-04-06 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 | U/L | 7-35 U/L | Normal | S |
| 1986-04-06 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 8-35 U/L | Normal | S |
| 1986-04-06 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 84 | U/L | 35-105 U/L | Normal | S |
| 1986-04-06 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1986-04-06 | Albumin [Mass/volume] in Serum or Plasma | 3.6 | g/dL | 3.5-5 g/dL | Normal | S |
| 1986-04-06 | Cancer Ag 125 [Units/volume] in Serum or Plasma | 1240 | U/mL | <=35 U/mL | High | S |
| 1986-04-06 | Carcinoembryonic Ag [Mass/volume] in Serum or Plasma | 1.6 | ng/mL | <=3 ng/mL | Normal | S |
| 1986-04-06 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 1986-04-06 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 5 | {score} | S | ||
| 1986-04-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 1986-04-14 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 8 | {score} | S | ||
| 1986-05-12 | Hemoglobin [Mass/volume] in Blood | 10.9 | g/dL | 11.6-15 g/dL | Low | S |
| 1986-05-12 | Leukocytes [#/volume] in Blood by Automated count | 6.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1986-05-12 | Neutrophils [#/volume] in Blood by Automated count | 4.2 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 1986-05-12 | Platelets [#/volume] in Blood by Automated count | 356 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1986-05-12 | Creatinine [Mass/volume] in Serum or Plasma | 0.68 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1986-05-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1981)/1.73 sq M | 114 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1986-05-12 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | 7-35 U/L | Normal | S |
| 1986-05-12 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | 8-35 U/L | Normal | S |
| 1986-05-12 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.4 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1986-05-12 | Albumin [Mass/volume] in Serum or Plasma | 3.7 | g/dL | 3.5-5 g/dL | Normal | S |
| 1986-05-12 | Magnesium [Mass/volume] in Serum or Plasma | 1.9 | mg/dL | 1.7-2.2 mg/dL | Normal | S |
| 1986-05-12 | Cancer Ag 125 [Units/volume] in Serum or Plasma | 188 | U/mL | <=35 U/mL | High | S |
| 1986-05-12 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 1986-05-12 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 2 | {score} | S | ||
| 1986-06-09 | Hemoglobin [Mass/volume] in Blood | 10.6 | g/dL | 11.6-15 g/dL | Low | S |
| 1986-06-09 | Leukocytes [#/volume] in Blood by Automated count | 2.9 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 1986-06-09 | Neutrophils [#/volume] in Blood by Automated count | 1.3 | 10*3/uL | 1.5-7.7 10*3/uL | Low | S |
| 1986-06-09 | Platelets [#/volume] in Blood by Automated count | 142 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 1986-07-14 | Hemoglobin [Mass/volume] in Blood | 10.3 | g/dL | 11.6-15 g/dL | Low | S |
| 1986-07-14 | Leukocytes [#/volume] in Blood by Automated count | 4.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1986-07-14 | Neutrophils [#/volume] in Blood by Automated count | 1.9 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 1986-07-14 | Platelets [#/volume] in Blood by Automated count | 188 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1986-07-14 | Creatinine [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1986-07-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1981)/1.73 sq M | 113 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1986-07-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-35 U/L | Normal | S |
| 1986-07-14 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.4 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1986-07-14 | Magnesium [Mass/volume] in Serum or Plasma | 1.7 | mg/dL | 1.7-2.2 mg/dL | Normal | S |
| 1986-07-14 | Cancer Ag 125 [Units/volume] in Serum or Plasma | 21 | U/mL | <=35 U/mL | Normal | S |
| 1986-07-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 1986-09-15 | Hemoglobin [Mass/volume] in Blood | 11.2 | g/dL | 11.6-15 g/dL | Low | S |
| 1986-09-15 | Leukocytes [#/volume] in Blood by Automated count | 4.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1986-09-15 | Neutrophils [#/volume] in Blood by Automated count | 2.6 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 1986-09-15 | Platelets [#/volume] in Blood by Automated count | 214 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1986-09-15 | Creatinine [Mass/volume] in Serum or Plasma | 0.69 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1986-09-15 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1981)/1.73 sq M | 113 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1986-09-15 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 | U/L | 7-35 U/L | Normal | S |
| 1986-09-15 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.4 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1986-09-15 | Cancer Ag 125 [Units/volume] in Serum or Plasma | 9 | U/mL | <=35 U/mL | Normal | S |
| 1986-09-15 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 1986-10-13 | Hemoglobin [Mass/volume] in Blood | 10.6 | g/dL | 11.6-15 g/dL | Low | S |
| 1986-10-13 | Leukocytes [#/volume] in Blood by Automated count | 4.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1986-10-13 | Neutrophils [#/volume] in Blood by Automated count | 2.4 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 1986-10-13 | Platelets [#/volume] in Blood by Automated count | 182 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1986-10-13 | Cholesterol [Mass/volume] in Serum or Plasma | 186 | mg/dL | <=200 mg/dL | Normal | S |
| 1986-10-13 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 58 | mg/dL | >=50 mg/dL | Normal | S |
| 1986-10-13 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 108 | mg/dL | <=129 mg/dL | Normal | S |
| 1986-10-13 | Triglyceride [Mass/volume] in Serum or Plasma | 98 | mg/dL | <=149 mg/dL | Normal | S |
| 1986-10-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S | ||
| 1986-10-13 | Total score [AUDIT-C] | 1 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1986-04-06 | Body height | 160 | cm | S |
| 1986-04-06 | Body weight | 58.5 | kg | S |
| 1986-04-06 | Body mass index (BMI) [Ratio] | 22.9 | kg/m2 | S |
| 1986-04-06 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1986-04-06 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1986-04-06 | Heart rate | 92 | /min | S |
| 1986-04-06 | Respiratory rate | 16 | /min | S |
| 1986-04-06 | Body temperature | 36.9 | Cel | S |
| 1986-04-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1986-04-14 | Body height | 160 | cm | S |
| 1986-04-14 | Body weight | 58.9 | kg | S |
| 1986-04-14 | Body mass index (BMI) [Ratio] | 23 | kg/m2 | S |
| 1986-04-14 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1986-04-14 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1986-04-14 | Heart rate | 96 | /min | S |
| 1986-04-14 | Respiratory rate | 16 | /min | S |
| 1986-04-14 | Body temperature | 36.8 | Cel | S |
| 1986-04-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1986-05-12 | Body height | 160 | cm | S |
| 1986-05-12 | Body weight | 55.2 | kg | S |
| 1986-05-12 | Body mass index (BMI) [Ratio] | 21.6 | kg/m2 | S |
| 1986-05-12 | Systolic blood pressure | 112 | mm[Hg] | S |
| 1986-05-12 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1986-05-12 | Heart rate | 84 | /min | S |
| 1986-05-12 | Respiratory rate | 14 | /min | S |
| 1986-05-12 | Body temperature | 36.7 | Cel | S |
| 1986-05-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1986-07-14 | Body height | 160 | cm | S |
| 1986-07-14 | Body weight | 55.9 | kg | S |
| 1986-07-14 | Body mass index (BMI) [Ratio] | 21.8 | kg/m2 | S |
| 1986-07-14 | Systolic blood pressure | 110 | mm[Hg] | S |
| 1986-07-14 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1986-07-14 | Heart rate | 80 | /min | S |
| 1986-07-14 | Respiratory rate | 14 | /min | S |
| 1986-07-14 | Body temperature | 36.6 | Cel | S |
| 1986-07-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1986-09-15 | Body height | 160 | cm | S |
| 1986-09-15 | Body weight | 56.8 | kg | S |
| 1986-09-15 | Body mass index (BMI) [Ratio] | 22.2 | kg/m2 | S |
| 1986-09-15 | Systolic blood pressure | 114 | mm[Hg] | S |
| 1986-09-15 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1986-09-15 | Heart rate | 76 | /min | S |
| 1986-09-15 | Respiratory rate | 14 | /min | S |
| 1986-09-15 | Body temperature | 36.6 | Cel | S |
| 1986-09-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1986-06-09 | Body height | 160 | cm | S |
| 1986-06-09 | Body weight | 55.8 | kg | S |
| 1986-06-09 | Body mass index (BMI) [Ratio] | 21.8 | kg/m2 | S |
| 1986-06-09 | Systolic blood pressure | 108 | mm[Hg] | S |
| 1986-06-09 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1986-06-09 | Heart rate | 88 | /min | S |
| 1986-06-09 | Respiratory rate | 16 | /min | S |
| 1986-06-09 | Body temperature | 37.5 | Cel | S |
| 1986-06-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1986-10-13 | Body height | 160 | cm | S |
| 1986-10-13 | Body weight | 57.2 | kg | S |
| 1986-10-13 | Body mass index (BMI) [Ratio] | 22.3 | kg/m2 | S |
| 1986-10-13 | Systolic blood pressure | 112 | mm[Hg] | S |
| 1986-10-13 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1986-10-13 | Heart rate | 74 | /min | S |
| 1986-10-13 | Respiratory rate | 14 | /min | S |
| 1986-10-13 | Body temperature | 36.6 | Cel | S |
| 1986-10-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1986-04-06 | Four weeks of bloating, early fullness and pelvic pain in a woman of 39: symptom index, pelvic examination, CA-125, and same-week imaging | finished | S |
| 1986-04-14 | Biopsy result: ovarian cancer; gynecologic oncology consultation, genetic counseling, and preparation for surgery | finished | S |
| 1986-05-12 | Review three weeks after cytoreductive surgery: pathology, genetic results, and the first cycle of chemotherapy | finished | S |
| 1986-07-14 | Midpoint of chemotherapy: CA-125, blood counts, neuropathy, and menopausal symptoms | finished | S |
| 1986-09-15 | End of chemotherapy: CT and CA-125 response, and the start of olaparib maintenance | finished | S |
| 1986-06-09 | Same-day sick visit for a cold during chemotherapy | finished | S |
| 1986-10-13 | Periodic adult preventive visit after ovarian cancer treatment | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Urgent gynecologic oncology consultation for a suspected ovarian cancer, before any surgery, to confirm the diagnosis and plan primary treatment | completed | GL-NCCN-OVARIAN-2026, GL-ACOG-CO716-2017 | S |
| At the first visit: the ovarian cancer symptom index, an abdominal and pelvic examination, CA-125 with CEA, blood count and chemistry, and a urine pregnancy test; transvaginal ultrasound and CT of the chest, abdomen and pelvis within the week, and image-guided biopsy if the scan shows disease outside the pelvis | completed | GL-GOFF-SI-2007, GL-ACOG-CO716-2017, GL-NCCN-OVARIAN-2026 | S |
| Genetic counseling and germline multigene panel testing (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 and the Lynch syndrome genes), as for every woman with epithelial ovarian cancer, and tumor testing for BRCA1 and BRCA2 and homologous recombination deficiency on the surgical specimen; if a germline variant is found, a family letter offering cascade testing to blood relatives | completed | GL-ASCO-OVGERM-2020, GL-NCCN-OVARIAN-2026 | S |
| Primary cytoreductive surgery by gynecologic oncology aiming for no visible residual disease, with enoxaparin for four weeks after the operation | completed | GL-NCCN-OVARIAN-2026, GL-ASCO-VTE-2023 | S |
| Carboplatin (AUC 5) and paclitaxel 175 mg/m2 every three weeks for six cycles, starting three weeks after surgery, after hepatitis B, hepatitis C and HIV screening; a three-drug antiemetic regimen on each treatment day; blood counts, kidney function and magnesium before each cycle; CA-125 each cycle; and neuropathy checks at every visit | completed | GL-NCCN-OVARIAN-2026, GL-ASCO-ANTIEMETIC-2020, GL-ASCO-CIPN-2020, GL-ASCO-HBV-2020 | S |
| Olaparib 300 mg twice daily as maintenance for two years after a complete response to platinum chemotherapy, chosen because the tumor carries a BRCA1 pathogenic variant; blood count monthly for the first year, with checks for fatigue, nausea, breathlessness and new cough | completed | GL-ASCO-PARP-2020, GL-NCCN-OVARIAN-2026 | S |
| Surgical menopause: symptom review at each visit, non-hormonal measures, a discussion of menopausal hormone therapy at the end of treatment, and a baseline bone density scan | completed | GL-NCCN-OVARIAN-2026, GL-SGO-SURV-2017 | S |
| Distress and depression screening at each visit, plain information, a cancer support community group, and survivorship care after treatment: a visit every three months for two years with examination and CA-125, and imaging only for symptoms or a rising CA-125 | completed | GL-SGO-SURV-2017, GL-NCCN-OVARIAN-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Tissue diagnosis and gynecologic oncology plan within two weeks of presentation | 1986-04-14 | completed | Ultrasound, CT and biopsy within four days; diagnosis and consultation on the eighth day | S |
| Cytoreductive surgery with no visible residual disease within three weeks of diagnosis | 1986-05-12 | completed | Complete gross resection one week after the diagnosis | S |
| Six cycles of carboplatin and paclitaxel every three weeks without a delay of more than one week | 1986-09-15 | completed | Six cycles completed on schedule; CT shows no evidence of disease and CA-125 is 9 | S |
| Germline and tumor genetic results available before the maintenance decision | 1986-09-15 | completed | Germline panel negative; tumor BRCA1 pathogenic variant; olaparib started | S |
| PHQ-9 below 10 throughout treatment, with a peer-support connection | 1986-09-15 | completed | PHQ-9 between 3 and 7; attends a cancer support community group | S |